HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CLR457

No structure or IUPAC name available; orally bioavailable pan-phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- CLR457: 1

Experts

1.	Baffert, Fabienne: 1 article (01/2019)
2.	Bauer, Todd M: 1 article (01/2019)
3.	Bedard, Philippe L: 1 article (01/2019)
4.	Doi, Toshihiko: 1 article (01/2019)
5.	Fabre, Claire: 1 article (01/2019)
6.	Harding, James J: 1 article (01/2019)
7.	Iyer, Varsha: 1 article (01/2019)
8.	Juric, Dejan: 1 article (01/2019)
9.	Radhakrishnan, Rajkumar: 1 article (01/2019)
10.	Rodon, Jordi: 1 article (01/2019)

Related Diseases

1.

Neoplasms (Cancer)

01/01/2019 - "Successive cohorts of patients with advanced solid tumors with PI3K pathway activation received increasing CLR457 doses according to a Bayesian escalation model based on the rate of dose limiting toxicity (DLT) in the first 28-day cycle. "
01/01/2019 - "Methods CLR457 anti-tumor activity and pharmacokinetics (PK) were characterized by in vitro biochemical assays and in vivo tumor xenografts. "
01/01/2019 - "CLR457 exhibited dose-dependent antitumor activity and interfered with glucose homeostasis in PI3K-mutant tumor xenografts. "

Related Drugs and Biologics

1.	Glucose (Dextrose)